ADC Therapeutics expects Q1 revenue of $19.24 million and a loss of $0.24 per share when it reports results on May 4, 2026. Consensus forecasts show a decline from the previous quarter’s $23.06 million in revenue, which had exceeded expectations by 7.8%.

Over the past 90 days, full-year 2026 revenue estimates for ADC Therapeutics have been lowered from $80.63 million to $76.64 million, while 2027 revenue forecasts fell from $148.88 million to $129.61 million. Earnings-per-share projections improved for 2026, rising from a -$1.08 loss to -$0.94, but worsened for 2027 to a -$0.76 loss.

Five analysts set a one-year average price target of $8.20, implying a 116.9% upside, with a high estimate of $10.00 and a low of $6.00. In contrast, the GF Value model suggests a fair value of $1.55, a 58.9% downside, while six brokerages maintain an average buy rating of 1.5 on the scale.